{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:49:32Z","timestamp":1787500172291,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Aegerion Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jacl.2015.11.011","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T02:48:20Z","timestamp":1448938100000},"page":"273-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design"],"prefix":"10.1016","volume":"10","author":[{"given":"Dirk J.","family":"Blom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi A.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Schwamlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnne","family":"Bloeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Underberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"45","key":"10.1016\/j.jacl.2015.11.011_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2015.11.011_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"issue":"32","key":"10.1016\/j.jacl.2015.11.011_bib4","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jacl.2015.11.011_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"13 Suppl","key":"10.1016\/j.jacl.2015.11.011_bib7","article-title":"Management of patients with homozygous familial hypercholesterolemia","volume":"19","author":"Ziajka","year":"2013","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacl.2015.11.011_bib8","first-page":"147","article-title":"Genetic screening for homozygous and heterozygous familial hypercholesterolemia","volume":"3","author":"Izar","year":"2010","journal-title":"Appl Clin Genet"},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","article-title":"Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy","volume":"227","author":"Bertolini","year":"2013","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.jacl.2015.11.011_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7537","key":"10.1016\/j.jacl.2015.11.011_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"issue":"9719","key":"10.1016\/j.jacl.2015.11.011_bib12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"9860","key":"10.1016\/j.jacl.2015.11.011_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2015.11.011_bib14","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25","author":"Marais","year":"2004","journal-title":"Clin Biochem Rev"},{"issue":"7","key":"10.1016\/j.jacl.2015.11.011_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/07853890.2014.931100","article-title":"Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia","volume":"46","author":"Sirtori","year":"2014","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.jacl.2015.11.011_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","article-title":"Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives","volume":"26","author":"Sjouke","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.avsg.2013.02.024","article-title":"Low-density lipoprotein levels and not mutation status predict intima-media thickness in familial hypercholesterolemia","volume":"28","author":"Fahed","year":"2014","journal-title":"Ann Vasc Surg"},{"issue":"8","key":"10.1016\/j.jacl.2015.11.011_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0002-9149(97)89309-5","article-title":"Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia","volume":"77","author":"Schmidt","year":"1996","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2015.11.011_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2013.08.035","article-title":"New EAS Consensus Statement on FH: improving the care of FH patients","volume":"231","author":"Stock","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.11.011_bib20","unstructured":"National Institute for Health and Clinical Excellence. Familial hypercholesterolaemia: Identification and management of familial hypercholesterolaemia.\u00a02008. Available at: http:\/\/www.nice.org.uk\/guidance\/cg71. (accessed 23 December 2015)."},{"key":"10.1016\/j.jacl.2015.11.011_bib21","unstructured":"International Atherosclerosis Society. IAS Position Paper: Global Recommendations for the Management of Dyslipidemia 2013 [cited 2014 August]. Available at: http:\/\/www.athero.org\/IASPositionPaper.asp. Accessed December 23, 2015."},{"issue":"1","key":"10.1016\/j.jacl.2015.11.011_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"issue":"25 Pt B","key":"10.1016\/j.jacl.2015.11.011_bib23","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on\u00a0Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.011_bib25","unstructured":"National Lipid Association. (Log in required) [cited 2014 August]. Available at: https:\/\/www.lipid.org\/patient-centered. Accessed December 23, 2015."},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacl.2014.01.002","article-title":"Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation","volume":"8","author":"Watts","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.011_bib27","unstructured":"National Institute for Health and Care Excellence. Identification and management of familial hypercholesterolaemia. Reviewed August 2011 [cited 2014 September]. Available at: http:\/\/www.nice.org.uk\/guidance\/cg71. Accessed December 23, 2015."},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.jacl.2015.11.011_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2015.11.011_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacl.2012.03.004","article-title":"Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia","volume":"6","author":"Graesdal","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2015.11.011_bib32","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/imj.12444","article-title":"Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies","volume":"44","author":"Page","year":"2014","journal-title":"Intern Med J"},{"issue":"12","key":"10.1016\/j.jacl.2015.11.011_bib33","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.acvd.2012.05.011","article-title":"Severe familial hypercholesterolaemia: current and future management","volume":"105","author":"Farnier","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2015.11.011_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/VHRM.S36641","article-title":"Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia","volume":"10","author":"Vuorio","year":"2014","journal-title":"Vasc Health Risk Manag"},{"issue":"9965","key":"10.1016\/j.jacl.2015.11.011_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacl.2015.11.011_bib36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.011_bib37","unstructured":"EMA. Lojuxta (lomitapide) 2014 [cited 2014 August]. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002578\/human_med_001668.jsp&mid=WC0b01ac058001d124. Accessed December 23, 2015."},{"key":"10.1016\/j.jacl.2015.11.011_bib38","unstructured":"FDA. Lomitapide orphan drug approval 2007 [cited 2014 August]. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/OOPD_Results_2.cfm?Index_Number=245907. Accessed December 23, 2015."},{"key":"10.1016\/j.jacl.2015.11.011_bib39","unstructured":"FDA. FDA approves new orphan drug for rare cholesterol disorder 2012 [cited 2014 August]. News release. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm333285.htm. Accessed December 23, 2015."},{"key":"10.1016\/j.jacl.2015.11.011_bib40","unstructured":"Aegerion Pharmaceuticals. Juxtapid prescribing information. 2014 [updated August 2014; cited 2015 March]. Available at: http:\/\/www.aegerion.com\/Collateral\/Documents\/English-US\/Prescribing%20Information%20August%202014.pdf. Accessed December 23, 2015."},{"issue":"3","key":"10.1016\/j.jacl.2015.11.011_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/01.CIR.104.3.249","article-title":"Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging","volume":"104","author":"Corti","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.011_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1532-429X-12-10","article-title":"Variations in atherosclerosis and remodeling patterns in aorta and carotids","volume":"12","author":"Hayashi","year":"2010","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacl.2015.11.011_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1532-429X-13-37","article-title":"Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness","volume":"13","author":"Migrino","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacl.2015.11.011_bib44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1749-6632.2001.tb03940.x","article-title":"New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in\u00a0vivo","volume":"947","author":"Corti","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.jacl.2015.11.011_bib45","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/ATVBAHA.113.302075","article-title":"Is carotid intima-media thickness as predictive as other noninvasive techniques for the detection of coronary artery disease?","volume":"34","author":"Zhang","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9802","key":"10.1016\/j.jacl.2015.11.011_bib46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jacl.2015.11.011_bib47","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2015.11.011_bib48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ahj.2013.12.008","article-title":"Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry","volume":"167","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2015.11.011_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/1744-1609.12023","article-title":"Role of international registries in enhancing the care of familial hypercholesterolaemia","volume":"11","author":"Hammond","year":"2013","journal-title":"Int J Evid Based Healthc"},{"issue":"1","key":"10.1016\/j.jacl.2015.11.011_bib50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cjca.2012.04.019","article-title":"Regional and national familial hypercholesterolemia registries: present international application, importance, and needs for Canada","volume":"29","author":"Al-Sarraf","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.011_bib51","unstructured":"Taiwan Society of Lipids & Atherosclerosis. Taiwan Familial Hypercholesterolemia Registry 2014 [cited 2014 September]. Available at: http:\/\/www.tas.org.tw\/?FID=60&CID=254. Accessed December 23, 2015."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328741500450X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328741500450X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T18:38:37Z","timestamp":1653676717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328741500450X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S193328741500450X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.11.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}